Media
The National Stroke Foundation is a not-for-profit organisation that works across the community to reduce the impact of stroke on all Australians. Follow media announcements via twitter @strokefdn.
Please contact Heather Potter hpotter@strokefoundation.com.au for current media releases or go to media in Library and Resources.
Current campaign/programs
Download: Budget response 15 May: Stroke catastrophe looming Budget offers nothing for vital stroke work
————————————————————————————————————————————————
The Deloitte Access Economics report, “The economic impact of stroke in Australia”, was commissioned by the National Stroke Foundation in 2012 and provides the first updated figures on the incidence, prevalence and cost of stroke in almost a decade.
- Media release Economics of Stroke 18 March 2013
- Deloitte Access Economics Report
- Deloitte Access Economics Report Summary 2013
NATIONAL ACTION PLAN FOR STROKE
National Stroke Foundation CEO Dr Erin Lalor today launched a National Action Plan for stroke in response to significant community concern about the way stroke is managed in Australia.
National Action Plan for Stroke
National Action Plan for Stroke Executive Summary
Media Release: National Action Plan for Stroke
Food for Thought Melbourne event
Media Release Food for Thought
Federal Government review of new anticoagulant treatments released
National Stroke Foundation chief executive Dr Erin Lalor:
“We welcome the Australian Government’s commitment to considering new oral anticoagulants, such as dabigatran, for the treatment of atrial fibrillation. Atrial fibrillation is a significant risk factor for stroke and many people with the condition cannot tolerate existing, currently-subsidised treatments – such as warfarin – and are therefore at an increased risk of stroke.
“We are pleased the Government’s review into these new anticoagulant treatments has now been finalised and released. The report concludes that the net benefit of new treatments “in clinical practice and the subsequent impact on cost-effectiveness is uncertain at this stage” and the Pharmaceutical Benefits Advisory Committee should review its March 2011 advice to list dabigatran on the Pharmaceutical Benefits Schedule.
“While we understand the need to ensure safety issues for new treatments are considered thoroughly and as a priority we are concerned for those people who are not able to take warfarin and will remain without access to alternative treatment. We urge the Government to conclude consideration of these issues as expeditiously as possible.”
Know your numbers
- Know your numbers TVC